Trial Profile
A Phase 2, Multicenter, Open-Label, Exploratory Biomarker Study of Talazoparib (BMN 673) Monotherapy in Patients with Recurrent or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2016
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Advanced breast cancer; Ovarian cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 02 Mar 2016 Status changed from recruiting to completed, according to European Clinical Trials Database record.
- 19 Aug 2015 New trial record